These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 18612199)

  • 1. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.
    Tsimihodimos V; Dounousi E; Siamopoulos KC
    Am J Nephrol; 2008; 28(6):958-73. PubMed ID: 18612199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines.
    Shoji T; Nishizawa Y
    Ther Apher Dial; 2006 Aug; 10(4):305-15. PubMed ID: 16911182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
    Molitch ME
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of lipid abnormalities associated with end-stage renal disease.
    Liu J; Kalantarinia K; Rosner MH
    Semin Dial; 2006; 19(5):391-401. PubMed ID: 16970739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid abnormalities in chronic renal failure, nephrotic syndrome and dialysis.
    Kes P
    Acta Med Croatica; 2001; 55(4-5):177-86. PubMed ID: 12398021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
    Kes P; Reiner Z; Brunetta B
    Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid metabolism in chronic kidney disease: the role of statins in cardiovascular risk.
    Wanner C; Drechsler C; Krane V
    J Ren Nutr; 2007 Jan; 17(1):75-8. PubMed ID: 17198938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure.
    Baber U; Toto RD; de Lemos JA
    Am Heart J; 2007 Apr; 153(4):471-7. PubMed ID: 17383281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular calcification in nondialyzed patients with chronic kidney disease.
    Qunibi WY
    Semin Dial; 2007; 20(2):134-8. PubMed ID: 17374087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach.
    Chmielewski M; Carrero JJ; Nordfors L; Lindholm B; Stenvinkel P
    J Nephrol; 2008; 21(5):635-44. PubMed ID: 18949717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.
    Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
    Expert Opin Pharmacother; 2010 Apr; 11(5):723-30. PubMed ID: 20210681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid metabolism in dialysis patients-the story gets more complicated.
    Ponda MP; Barash I
    Semin Dial; 2008; 21(5):390-4. PubMed ID: 18764791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dyslipidemia and the risk of kidney disease].
    Ligabue G; Cavazzini F; Albertazzi A
    G Ital Nefrol; 2007; 24 Suppl 38():8-12. PubMed ID: 17922441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between body mass index and body fat in chronic kidney disease stages 3 to 5, hemodialysis, and peritoneal dialysis patients.
    Leinig C; Pecoits-Filho R; Nascimento MM; Gonçalves S; Riella MC; Martins C
    J Ren Nutr; 2008 Sep; 18(5):424-9. PubMed ID: 18721737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Statins: what is their place in the treatment of chronic kidney insufficiency?].
    Ponte B; Bourquin V; Stoermann-Chopard C
    Rev Med Suisse; 2009 Feb; 5(192):463-4, 466-8. PubMed ID: 19317313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.